Neuropathic Pain: The Evidence-Based Supplement Protocol

← Back to articles

Neuropathic pain spans diabetic painful neuropathy, post-herpetic neuralgia, chemotherapy-induced peripheral neuropathy, radiculopathy, and other nerve-injury syndromes. Guideline-recommended first-line therapy is pharmacologic — gabapentinoids (gabapentin, pregabalin), SNRIs (duloxetine), tricyclic antidepressants, and topical agents (lidocaine, capsaicin). A handful of supplements have controlled-trial evidence as adjuncts, with the most data in diabetic peripheral neuropathy, but effect sizes are generally modest and the quality of evidence is uneven. None should replace proven analgesic pharmacotherapy in moderate-to-severe pain.

Alpha-lipoic acid (ALA) — 600 mg daily (moderate evidence, diabetic neuropathy)

Alpha-lipoic acid is the best-supported supplement for painful diabetic neuropathy. The SYDNEY 2 RCT (181 adults) showed oral ALA 600 mg/day for 5 weeks reduced the Total Symptom Score by about 51% versus 32% on placebo, with stabbing and burning pain among the symptoms that improved; doses above 600 mg added side effects without added benefit. A 2022 systematic review and meta-analysis of randomized trials confirmed ALA significantly lowers neuropathic symptom scores (including burning, stabbing, paresthesia, and numbness) in diabetic polyneuropathy, via both oral and IV routes. Evidence outside diabetes is limited. Take on an empty stomach. See our ALA piece.

Palmitoylethanolamide (PEA) — ~600 mg/day (limited evidence, low-certainty)

Palmitoylethanolamide is an endogenous fatty-acid amide acting through PPAR-α and mast-cell modulation. A 2023 systematic review and meta-analysis of 11 double-blind RCTs (774 patients) found PEA reduced pain scores versus comparators with a standardized mean difference of about 1.68 and no major safety signals; a 2022 review of nociceptive, musculoskeletal, and neuropathic pain also reported benefit. Both reviews flag important caveats — high statistical heterogeneity and signs of publication bias — so the certainty is low and larger rigorous trials are needed. Reasonable as an adjunct; not a substitute for first-line drugs. See our PEA piece.

Benfotiamine — 300–600 mg daily (limited evidence)

Benfotiamine is a fat-soluble thiamine derivative with better tissue uptake than thiamine HCl. The BENDIP RCT (133–165 adults) found the Neuropathy Symptom Score improved significantly in per-protocol analysis (p=0.033) but only borderline in intention-to-treat (p=0.055), and the Total Symptom Score did not reach significance at 6 weeks; benefit was greater at the higher dose and longer duration. A Cochrane B-vitamin review noted a small vibration-perception benefit but judged the overall evidence insufficient. A fair trial, well tolerated, modest expectations. See the fat-soluble thiamine piece.

Vitamin B12 — only if deficient

Long-term metformin and proton-pump inhibitor use can deplete B12, and documented deficiency causes a neuropathy that responds to repletion. Screen B12 (with methylmalonic acid if borderline) in those at risk and replete with hydroxocobalamin or high-dose oral B12. This is correction of a deficiency, not a general analgesic. See the B12 form piece.

Acetyl-L-carnitine — weak, and a cautionary case (insufficient evidence)

Some older industry-funded trials suggested acetyl-L-carnitine helped diabetic neuropathy, but a 2019 Cochrane review (4 trials, 907 patients) rated the pain evidence very low certainty, with benefit only above 1,500 mg/day. More striking, a large randomized trial in women on taxane chemotherapy found acetyl-L-carnitine significantly increased chemotherapy-induced neuropathy by 24 weeks — the authors concluded patients should be discouraged from using unproven supplements. So ALCAR is not recommended for chemotherapy-induced neuropathy and is unproven elsewhere. See the ALCAR vs LCAR piece.

What doesn't work, or can harm

High-dose vitamin B6 causes neuropathy. Chronic intake above ~100 mg/day produces a sensory neuropathy, so avoid "nerve-support" megavitamin formulas that load B6. As above, acetyl-L-carnitine worsened chemotherapy-induced neuropathy in a major trial. Avoid kava (hepatotoxicity). CBD has thin neuropathy-specific clinical data and frequent label-accuracy issues. And no supplement should replace gabapentinoid, SNRI, or tricyclic therapy when pain is moderate-to-severe.

How to run the protocol

Identify and treat the underlying cause — glycemic control is foundational in diabetes. Screen B12 (especially in metformin users) and replete if deficient. A reasonable adjunctive trial is ALA 600 mg/day, with benfotiamine 300 mg/day, reassessed at about 12 weeks; PEA can be added for residual pain with the caveats above. Pair these with guideline first-line analgesics rather than relying on supplements alone, and avoid the harmful options listed above. See the peripheral neuropathy page.